These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 26484982)

  • 41. Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.
    Mesquita Augusto Passos R; Feldens TK; Marcolino MAZ; Gouvêa AS; Dos Santos Oliveira L; Menardi Nasser L; Rodrigues RF; de Lourdes Martins Perobelli L; Campolina AG; de Almeida Neto C
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):15-28. PubMed ID: 36285481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.
    Milone G; Tripepi G; Martino M; Ancora F; Bartolozzi B; Spadaro A; Nozzoli C; La Fauci A; Amico I; Leotta S; Poidomani M; Irrera G; Iacopino P; Saccardi R; Guidi S; Bosi A
    Blood Transfus; 2013 Jan; 11(1):94-101. PubMed ID: 23114516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
    Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
    Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
    Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
    Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].
    Duan WB; Dou XL; Lei L; Wang FR; Huang XJ; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):21-26. PubMed ID: 33677864
    [No Abstract]   [Full Text] [Related]  

  • 48. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
    Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
    Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
    Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
    Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T; Sullivan HC; Hendrickson JE
    J Clin Apher; 2024 Jun; 39(3):e22127. PubMed ID: 38803152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
    Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
    Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis.
    Yang X; Wan M; Yu F; Wang Z
    Exp Ther Med; 2019 Aug; 18(2):1141-1148. PubMed ID: 31363366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.
    He D; Zhu C; Guo X; Huang X; Han X; Zheng G; Zhao Y; Yang Y; Wu W; Ge J; Zhang E; He J; Cai Z
    Transfus Apher Sci; 2023 Jun; 62(3):103618. PubMed ID: 36481258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.